Mutations in TP53 and KRAS, frequently observed in NSCLC, are associated with enhanced tumor mutational burden, increased PD-L1 expression, and altered immune microenvironment, potentially contributing to improved responsiveness to ICIs. This evidence concerns the gene KRAS and neoplasm.